Drug Trial Radar · NCT06973681
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Oct 13, 2023
Primary completion
Sep 13, 2024
Study completion Sep 13, 2024
Sponsor
- Lead sponsor
- BrightGene Bio-Medical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.
Conditions
- Overweight or Obesity
Interventions
BGM0504Drug
Administered SC
BGM0504Drug
Administered SC
BGM0504Drug
Administered SC
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in body weightTime frame: Week 0 to Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Third Xiangya Hospital of Central South University
Changsha, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.